Drug Eluting Device Slows Vision Loss in Geographic Atrophy Brought on by Dry AMD

April 11, 2011

A new study, recently published in the Proceedings of the National Academy of Sciences (PNAS) shows that a potential treatment for the advanced stage of dry AMD, geographic atrophy (GA), can be used to slow vision loss in this blinding condition that affects more than a million people.

Neurotech Pharmaceuticals’ NT-501 drug eluting device can be placed in the vitreous of those suffering from GA and will deliver a neuroprotective agent, ciliary neurotrophic factor (CNTF), for up to a year and should result in preservation of vision.

NT-501 is not yet FDA approved, as further testing will be required before marketing can occur.

To read more about this development, please follow the link.




Jump down to form below to submit your own comments

Comments are closed.